NCT06276270 - Multi-centre, Open-label, First-in-man Study With Mucopad HA | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Oral Mucositis

Interventions

DEVICE

Mucopad HA

The product is a Class III Medical Device incorporating a medicinal substance (antiseptics-octenidine) within the composition made of sodium hyaluronate polysacharide stabilised by calcium chloride. Device is administered directly onto the area affected by mucositis.

Trial Locations (5)

56401

RECRUITING

Masarykův onkologický ústav, Klinika radiační onkologie, Brno

RECRUITING

FN Hradec Králové Klinika onkologie a radioterapie, Hradec Králové

RECRUITING

Fakultní nemocnice Ostrava, Klinika onkologická, Ostrava

RECRUITING

Etická komise FN Bulovka, Prague

RECRUITING

Fakultní Thomayerova nemocnice Onkologická klinika 1.LF UK a FTN, Prague